July 1, 2022
2 mins read

Omicron variants: US FDA backs Covid boosters

The Omicron BA.4 and BA.5 variants, currently driving the fresh wave of Covid cases globally, are known to evade vaccine induced immunity….repors Asian Lite News

The US Food and Drug Administration (FDA) has recommended vaccine manufacturers to develop booster shots against Covid-19 targeting Omicron BA.4 and BA.5 variants.

While currently available vaccines have helped reduce hospitalisation and death caused by Covid, results from several observational studies have shown that effectiveness of primary vaccination wanes over time against certain variants, including Omicron.

The Omicron BA.4 and BA.5 variants, currently driving the fresh wave of Covid cases globally, are known to evade vaccine induced immunity.

The FDA recommendation is based on the advice of independent experts on the Vaccines and Related Biological Products Advisory Committee that voted in favour of including a SARS-CoV-2 Omicron component in Covid-19 vaccines that would be used for boosters in the US beginning in September.

“As we move into the fall and winter, it is critical that we have safe and effective vaccine boosters that can provide protection against circulating and emerging variants to prevent the most severe consequences of Covid-19,” said Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research, in a statement on Thursday.

“We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an Omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine, so that the modified vaccines can potentially be used starting in early to mid-fall 2022,” he added.

The FDA, however, has not advised manufacturers to change the vaccine for primary vaccination, since it provides a base of protection against serious outcomes of Covid-19 caused by circulating strains of SARS-CoV-2.

Vaccine manufacturers like Pfizer, Moderna, and Novavax have already been testing Omicron-targeted versions of their shots.

Their early data, based on the BA.1 variant, promises a stronger immune response to the Omicron variant than existing shots.

The FDA advised the drugmakers to conduct additional clinical trials on BA.4 and BA.5 shots, as well as send in data from the BA.1 shots to the agency for evaluation.

ALSO READ: Indian-origin entrepreneur booked for $45mn investment fraud in US

Previous Story

India, Saudi Arabia agree to enhance defence cooperation

Next Story

Community to convert single-use plastic into reusable bags

Latest from -Top News

Porn sites to begin strict age checks

Under the Online Safety Act, age verification and age estimation must be “highly effective” at correctly determining whether a user is under 18 for sites hosting harmful content Major pornography sites including

Miliband shuns £25bn renewable energy project

Whitehall sources say the government will emphasise a desire to focus on “homegrown” energy in a statement explaining its rejection of the Xlinks project The government is snubbing a £25bn renewable energy
Go toTop

Don't Miss

Melania Trump Steals Spotlight

Melania Trump launched her cryptocurrency $MELANIA, tanking her husband’s cryptocurrency

India, US ink Investment Incentive Agreement  

The agreement supersedes another similar pact signed between the governments